Cord Blood News Volume 2.31 | Aug 19 2010

ROCK Inhibitor Y-27632 Increases Thaw-Survival Rates and Preserves Stemness and Differentiation Potential of Human Wharton’s Jelly Stem Cells After Cryopreservation 
Researchers examined the role of Y-27632 on human umbilical cord Wharton’s jelly stem cells for (1) thaw-survival (2) proliferation and (3) preservation of stemness and differentiation potential after cryopreservation. [Stem Cell Rev]

Enumerate total hematopoietic progenitors (CFC) in cord blood units in only 7 days with MethoCult® Express by STEMCELL Technologies     REQUEST A SAMPLE

Blood Stem Cell, Leukemia Link Illuminated
Researchers have discovered at least one key reason why blood stem cells are susceptible to developing the genetic mutations that can lead to adult leukemia. [Press release from the University of California, San Francisco discussing online prepublication in Cell Stem Cell]

Chronic Health Conditions Common for Stem Cell Transplant Survivors
Although hematopoietic cell transplantation cures many blood diseases, two-thirds of long-term survivors report at least one chronic health condition after the procedure. [Press release from the American Society of Hematology discussing online prepublication in Blood]

MicroRNA Molecule Increases Number of Blood Stem Cells, May Help Improve Cancer Treatment
Researchers identified a tiny RNA molecule that increases the number of hematopoietic stem cells, an advance that may improve treatment of blood system cancers. [Press release from Massachusetts General Hospital discussing online prepublication in the Proceedings of the National Academy of Sciences USA]

Scientific Breakthrough as Red Blood Cells Are Made from IVF Embryos
British scientists have turned stem cells from spare IVF embryos into red blood cells as part of a project to manufacture synthetic blood on an industrial-scale. [The Independent]

		Learn about our GLP compliant Contract Assay Services WATCH THE VIDEO
		WWW.CONTRACTASSAY.COM | WWW.STEMCELL.COM

The Transcription Factor SRF Regulates Hematopoietic Stem Cells Adhesion
Results demonstrate that serum response factor (Srf) is an essential regulator of stem cells and multipotent progenitor adhesion and suggest that Srf acts mainly through cell-matrix interactions and integrin signaling. [Blood]
 
MicroRNA miR-125a Controls Hematopoietic Stem Cell Number
Researchers report that the microRNA processing enzyme Dicer is essential for stem cell persistence in vivo and a specific microRNA, miR-125a, controls the size of the stem cell population by regulating hematopoietic stem/progenitor cell apoptosis. [Proc Natl Acad Sci U S A]

Osteogenic Differentiation of Intact Human Amniotic Membrane
Stem cells within human amniotic membrane can successfully be driven along the osteogenic pathways while residing within their natural environment. [Biomaterials]

Human CD4+CD25+ Cells in Combination with CD34+ Cells and Thymoglobulin to Prevent Anti-Hematopoietic Stem Cell T Cell Alloreactivity
Findings suggest that human autologous or allogeneic regulatory T cells could be co-transplanted with CD34+ cells after preparative regimens including thymoglobulin. [Biol Blood Marrow Transplant]

Graft Source Determines Human Hematopoietic Progenitor Distribution Pattern Within the CD34+ Compartment
Findings show that a better understanding of the progenitor compartment in human hematopoietic grafts could lead to improved strategies for the development of cellular therapies, for example in situations where platelet engraftment is delayed. [Bone Marrow Transplant]

Cryo-Cell Announces Célle(SM) Research and Development Collaboration with Department of Medicine, Monash University
Cryo-Cell International, Inc. announced a research and development collaboration agreement with Monash University in Australia. [Cryo-Cell International, Inc. Press Release]

Cryo-Cell International to Explore Strategic Acquisition Opportunities
Cryo-Cell International, Inc. announced that it has engaged Morgan Joseph LLC to evaluate strategic acquisition opportunities available to enhance value for Cryo-Cell’s shareholders. [Cryo-Cell International, Inc. Press Release]
 
International Society for Cellular Therapy (ISCT) Joins Forces with Roche and Genzyme to Launch Cell Therapy Industry Partnership
Many companies in the cell therapy regenerative medicine market including Roche, Genzyme, Athersys, Miltenyi Biotec, Hospira, Lonza and Life Technologies will join ISCT to launch a series of new initiatives that will create greater strategic alignment within the industry and drive late stage clinical development. [International Society for Cellular Therapy Press Release]

ASH Recommends Cross-Disciplinary Engagement to Advance Regenerative Medicine
The American Society of Hematology (ASH) has developed specific recommendations to the scientific community and federal agencies to help propel collaborative research in regenerative medicine in order to make real strides in improving patient care. These recommendations were released in Blood. [American Society of Hematology Press Release]

Proteonomix, Inc. Announces Joint Venture in the United Arab Emirates
Proteonomix, Inc. announced that it has executed a joint venture agreement with a group of investors that will create a new stem cell treatment and research facility in the United Arab Emirates. [Proteonomix, Inc. Press Release]

Emerging Healthcare Solutions Inks Option for Breakthrough Stem Cell Technology
Emerging Healthcare Solutions, Inc. announced that the Company has signed an option with Regenevita, owner of the right to license Neo Natal Progenitor Cell Expansion Technology in Latin America. [Business Wire]

NSF Awards $3 Million Stem Cell Bio-Manufacturing Program to Georgia Tech
The National Science Foundation (NSF) has awarded $3 million to the Georgia Institute of Technology to fund a unique research program on stem cell bio-manufacturing. [Georgia Institute of Technology Press Release]

Mesoblast on Track for Phase III Bone Marrow Transplant Trial Following Positive Meeting with FDA
Australian regenerative medicine company, Mesoblast Limited provided market guidance on its Phase III bone marrow transplant program following a formal meeting with the United States Food and Drug Administration (FDA). [Mesoblast Limited Press Release]

Genmab Announces Top-Line Interim Results for Ofatumumab in Diffuse Large B-Cell Lymphoma
Genmab A/S announced top-line interim results from an initial Phase II single arm open label study of ofatumumab to evaluate the treatment of relapsed Diffuse Large B-Cell Lymphoma in patients ineligible for or relapsed following a stem cell transplant. [Genmab A/S Press Release]

Sanofi Seeks Efficiencies with New Model
Sanofi-aventis is dividing its vast resources into decentralized disease-based units, each with its own departments for research and development, regulatory affairs, marketing, and sales — a plan designed to identify promising drugs more quickly and weed out failures before spending billions on unsuccessful clinical trials. [The Boston Globe]

Enhancing Research in Regenerative Medicine
The American Society of Hematology (ASH) convened a working group of experts from the fields of hematopoietic stem cell biology, embryonic stem cells, transplantation biology, and gene therapy at the urging of the Committee on Government Affairs with the goal of developing a “white paper” to inform recommendations to ASH and appropriate parties at the National Institutes of Health about the need for additional research in the area of regenerative medicine. [Blood]

EMA and U.S. FDA Seek Potential Candidate Companies for Joint GMP Inspection Program
The European Medicines Agency (EMA) and the Food and Drug Administration of the United States of America (U.S. FDA) continue to seek potential candidate companies for a joint GMP inspection pilot programmed for manufacturers of medicinal products. [European Medicines Agency, European Union]

Exceptional, Unconventional Research Enabling Knowledge Acceleration (EUREKA) (R01) (RFA-GM-11-003) [National Institutes of Health, United States]

National Heart, Lung, and Blood Institute; Notice of Closed Meetings (FR Doc. 2010-20291) [National Institutes of Health, United States]
 
NIH-RAID Updates on Program Scope and Procedures: Biologics Manufacture, Lead Selection, and Product Development Plans (NOT-RM-10-012) [National Institutes of Health, United States]

Clarification of Eligible Institutions for PAR-10-221 (R01) and PAR-10-222 (R21): Biophysical and Biomechanical Aspects of Embryonic Development (NOT-HD-10-020) [National Institutes of Health, United States]

Proposed Collection; Comment Request; NIH NCI Central Institutional Review Board (CIRB) Initiative (NCI) (FR Doc. 2010-20167) [National Institutes of Health, United States]

Center for Scientific Review; Notice of Closed Meeting (FR Doc. 2010-20287) [National Institutes of Health, United States]
 
Office of the Director, National Institutes of Health; Notice of Meeting (FR Doc. 2010-20021) [National Institutes of Health, United States]
 
National Human Genome Research Institute; Notice of Closed Meeting (FR Doc. 2010-19939) [National Institutes of Health, United States]
 
Basic Research on Self-Regulation (R21) (RFA-AG-11-010) [National Institutes of Health, United States]
 
National Center for Research Resources; Notice of Meeting (FR Doc. 2010-20014) [National Institutes of Health, United States]

Limited Pilot for National Institute of General Medical Sciences Legacy Community-Wide Scientific Resources (R24) (PAR-10-261) [National Institute of General Medical Sciences, United States]
 
7342.007 Addendum – Imported Human Cells, Tissues, and Cellular and Tissue-Based Products (HCT/Ps) [Center for Biologics Evaluation and Research, United States]

Comprehensive List of Guidance Documents at the Food and Drug Administration [Docket No. FDA-1998-N-0050] (formerly Docket No. 1998N-0046) [Food and Drug Administration, United States]

EVENTS (Listed by Date)

Select Biosciences 3rd Annual Stem Cells Europe Conference
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences World Biobanking Summit
August 24-25, 2010
Edinburgh, Scotland

Select Biosciences Inaugural Cellular Therapy Summit
August 24-25, 2010
Edinburgh, Scotland

International Society for Cellular Therapy – Europe 2nd Regional Meeting
September 11-14, 2010
Belgirate, Italy

Stem Cells USA & Regenerative Medicine Congress 2010
September 13-15, 2010
Philadelphia, United States

Tissue Engineering & Regenerative Medicine International Society (TERMIS) – Asia Pacific 2010
September 15-17, 2010
Sydney, Australia

International Society for Hematology and Stem Cells (ISEH) 2010 Meeting
September 15-18, 2010
Melbourne, Australia

Cellular Therapy of Cancer Symposium – ATTACK Project Meeting
September 24-27, 2010
Montpellier, France

International Society for Cell and Gene Therapy of Cancer (ISCGT) Congress
September 27-29, 2010
Doha, Qatar

5th Annual Meeting of the German Society for Stem Cell Research
September 30-October 2, 2010
Lübeck, Germany

AABB (formerly known as the American Association of Blood Banks) Annual Meeting & Cellular Therapy and Transfusion Medicine Expo (CTTXPO) 2010
October 9-12, 2010
Baltimore, United States

Institute for Genomic Medicine Inaugural Symposium
October 11-12, 2010
San Diego, United States

5th Annual Translational Stem Cell Research Conference
October 12-13, 2010
New York City, United States

Fraunhofer Life Science Symposium Leipzig 2010
October 29-30, 2010
Leipzig, Germany

NEW BioMalaysia 2010 Conference and Exhibition
November 2-4, 2010
Kuala Lumpur, Malaysia

World Cord Blood Congress
November 4-7, 2010
Marseille, France

Cambridge Healthtech Institute’s Inaugural Stem Cells in Drug Discovery and Development
November 8-9, 2010
San Diego, United States

Select Biosciences 2nd International Forum on Stem Cells (2010 IFSC)
November 12-13, 2010
Tianjin, China

The 16th International Conference of the International Society of Differentiation: From Stem Cells to Organisms
November 15-18, 2010
Nara, Japan

Stem Cell Network’s 10th Annual Scientific Meeting
November, 22-24, 2010
Calgary, Alberta

52nd American Society of Hematology (ASH) Annual Meeting and Exposition
December 4-7, 2010
Orlando, United States

Select Biosciences 5th Annual Stem Cells World Congress
January 24-25, 2011
San Diego, United States

Visit our events page to stay up to date with the latest events in the cell, gene and immunotherapy community.

JOB OPPORTUNITIES

Cell Therapy Technologist (Opexa Therapeutics)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities with Cord Blood News.

Visit here to post your career opportunities.

Have we missed an important article or publication in Cord Blood News? Click here to submit!

Comments or Suggestions? Email info@connexoncreative.com with your feedback.